DICE Therapeutics, Inc.
Save
2.27B
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications.
Similar securities
Based on sector and market capitalization
Report issue